Systemic Lupus Erythematosus
Conditions
Keywords
Systemic lupus erythematosus, Aging
Brief summary
The study aims at evaluating the phenomena of immune system aging in patients with Systemic lupus erythematosus.
Detailed description
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by a breakdown of tolerance against nuclear antigens. Thanks to improvements during the last decades in diagnosis, therapeutics and medical care, the lifespan of SLE patients has remarkably increased. However, standardized mortality ratio are still high in this population, with an increased mortality and morbidity associated with cardiovascular events and infectious events. Interestingly, these conditions are more commonly found during old age in the general population, raising the question of the presence of an acceleration of the aging process in SLE patients. It has been demonstrated that the aging of the immune system, i.e. immunosenescence, is a key player in the development of many age-related diseases. The acceleration of immunosenescence, as it is observed during chronic viral infections for example, could favor the premature occurrence of clinical manifestations of accelerated aging. The exact contribution of such phenomenon in the context of SLE has, so far, never been explored. Here, the investigators propose to perform a comprehensive study of the phenomena of immune system aging in patients with SLE in comparison to age-matched healthy controls. The study will recruit 50 SLE patients followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected at study visit to extensively evaluate immune system aging. Fundamental research will be realized on patients' samples. Patients will be included within their usual follow-up. No extra visit will be needed, and blood samples will be drawn at the same time as those drawn for clinical purposes.
Interventions
BIOLOGICALblood sample
48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
Sponsors
University of Bordeaux
Institut National de la Santé Et de la Recherche Médicale, France
University Hospital, Bordeaux
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* male or female; * age between 18 and 60 years; * Lupus patient : diagnosis of systemic lupus erythematosus according to ACR or SLICC criteria; * being affiliated to health insurance; * willing to participate and to sign informed consent.
Exclusion criteria
* pregnant or breastfeeding women; * persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Absolute numbers of naïve T lymphocytes | At baseline (Day 0) |
Secondary
| Measure | Time frame |
|---|---|
| Percentages of terminally differentiated T lymphocytes among total lymphocytes | At baseline (Day 0) |
| Percentages of senescent lymphocytes among total lymphocytes | At baseline (Day 0) |
| Telomere length in sorted CD4+ and CD8+ T lymphocytes subsets (naïve and memory) | At baseline (Day 0) |
| Frequency and phenotype of ELA-specific CD8+ T-cells after 10 days of in vitro priming | At baseline (Day 0) |
| Number of naïve T lymphocytes newly produced by thymus evaluated by T-cell receptor excision circles (TRECs) measurement | At baseline (Day 0) |
| Concentrations of senescence-associated secretory phenotype (SASP) markers in patients sera | At baseline (Day 0) |
| Absolute numbers of terminally differentiated T lymphocytes | At baseline (Day 0) |
| Measurement of disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) | At baseline (Day 0) |
| Measurement of disease activity according to British Lupus Assessment Group Index 2004 (BILAG-2004) | At baseline (Day 0) |
| Quantification of organ damage according to SLICC/ACR Damage Index | At baseline (Day 0) |
| Levels of anti-double stranded DNA in patients sera | At baseline (Day 0) |
| Levels of complement components C3 and C4 in patients sera | At baseline (Day 0) |
| Presence or absence of anti-type I interferons autoantibodies in patients sera | At baseline (Day 0) |
Countries
France
Contacts
Primary ContactNoemie GENSOUS, MD
Outcome results
None listed